에서 실시간으로 운영 중이에요! 자세히 알아보기

Denali Therapeutics

DNLI

시가총액 US$28.1억

17.61 USD

-0.73

3.98%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

17.60

-0.01

0.06%

1일

-3.98%

5일

-8.9%

1개월

-12.21%

3개월

-22.53%

6개월

-14.97%

연초 이후

8.24%

1년

5.32%

5년

-61.04%

10년

-17.9%

소개: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

직원 수: 507

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 36.4%

중립 54.5%

부정적 9.1%

CNBC Television

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zacks Investment Research

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali Therapeutics: Bullish On Avlayah And Their Prospects

AVLAYAH's approval has helped validate Denali Therapeutics' TransportVehicle platform. They're now moving into their commercial stage as a business. Early payer coverage and Q3 guidance support a credible launch ramp. However, AVLAYAH's US label limits its near-term potential. Zafinofusp alfa and four TV-enabled 2027 readouts provide meaningful pipeline upside beyond AVLAYAH.

Denali Therapeutics: Bullish On Avlayah And Their Prospects

Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One

Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodegenerative markets.

Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One

Zacks Investment Research

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics Q2 Earnings Call Highlights

Denali Therapeutics NASDAQ: DNLI reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded payer access and advanced two Alzheimer's disease programs into clinical development.

Denali Therapeutics Q2 Earnings Call Highlights

Zacks Investment Research

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.72 per share a year ago.

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue Advanced TransportVehicle™ portfolio with two Alzheimer's disease programs now in clinical development $195 million in gross proceeds received in July 2026 from sale of a Priority Review Voucher, bringing pro forma cash, cash equivalents and marketable securities to more than $1.1 billion Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.